Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004 Aug 01;104(3):655-8

Date

04/10/2004

Pubmed ID

15073032

DOI

10.1182/blood-2003-07-2345

Scopus ID

2-s2.0-3242816208 (requires institutional sign-in at Scopus site)   118 Citations

Abstract

Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study aims to describe the complications and outcomes of a subset of patients with mycosis fungoides/Sézary syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) that mostly improved after alemtuzumab discontinuation. The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation.

Author List

Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Aged
Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Agents
Arrhythmias, Cardiac
Female
Heart
Heart Failure
Humans
Male
Middle Aged
Mycosis Fungoides
Myocardium
Retrospective Studies
Sezary Syndrome